Trial
NCT02357732
Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Pittsburgh
Collaborators
Bristol-Myers Squibb
Condition
Metastatic Melanoma
Intervention
Nivolumab
Why stopped
PI decided not to proceed
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-12-11